Provided by Tiger Trade Technology Pte. Ltd.

Novo-Nordisk A/S

36.04
-0.3600-0.99%
Post-market: 36.060.0200+0.06%19:59 EDT
Volume:14.69M
Turnover:531.60M
Market Cap:159.98B
PE:9.95
High:36.49
Open:36.31
Low:35.89
Close:36.40
52wk High:81.44
52wk Low:35.85
Shares:4.44B
Float Shares:3.19B
Volume Ratio:0.78
T/O Rate:0.46%
Dividend:1.72
Dividend Rate:4.78%
EPS(TTM):3.62
EPS(LYR):3.62
ROE:60.70%
ROA:17.43%
PB:5.60
PE(LYR):9.95

Loading ...

Mixed options sentiment in Novo Nordisk with shares down 1.09%

TIPRANKS
·
14 hours ago

Novo Nordisk A/S Stock Falls Friday, Outperforms Market

Dow Jones
·
16 hours ago

Novo Nordisk says Awiql approved by FDA in type 2 diabetes patients

TIPRANKS
·
Yesterday

What's Happening With Novo Nordisk Stock Today?

Benzinga
·
Yesterday

Novo Nordisk AGM Backs 2025 Dividend, Expands Capital Mandates and Refreshes Board

TIPRANKS
·
Yesterday

Novo Nordisk Shareholders Approve Dividend, Buyback

MT Newswires Live
·
Yesterday

Novo Nordisk’s FDA-Approved Glp-1S NOW Available With Hims & Hers

THOMSON REUTERS
·
Yesterday

Novo Nordisk announces resolutions from annual meeting

TIPRANKS
·
Mar 26

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

MT Newswires Live
·
Mar 26

Deutsche Bank Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

TIPRANKS
·
Mar 26

Novo Nordisk call volume above normal and directionally bullish

TIPRANKS
·
Mar 26

BREAKINGVIEWS-Novo Nordisk is Denmark’s big little problem: podcast

Reuters
·
Mar 26

Novo Nordisk A/S Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Mar 26

Is Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?

Benzinga_recent_news
·
Mar 25

J.P. Morgan Sticks to Their Hold Rating for Novo Nordisk (0QIU)

TIPRANKS
·
Mar 25

Novo Nordisk Says Experimental Diabetes and Obesity Drug Shows Positive Results -- Update

Dow Jones
·
Mar 25

Novo Nordisk A/S Stock Falls Monday, Underperforms Market

Dow Jones
·
Mar 24

Norway's Oil Fund to Abstain From Voting for Re-Election of Novo Nordisk Chairman

Dow Jones
·
Mar 23

Lexicon, Novo Nordisk announce initiation of LX9851 study

TIPRANKS
·
Mar 23

Novo Nordisk's Weight-Loss Pill Continues to Impress -- Market Talk

Dow Jones
·
Mar 23